ATYR1923 Is Safe, Well-tolerated by Pulmonary Sarcoidosis Patients, Phase 1/2 Trial Shows
ATYR1923, aTyr Pharma’s lead investigational therapy for pulmonary sarcoidosis, is safe and well-tolerated, according to interim data from a Phase 1b/2a clinical trial. ATYR1923 is a first-in-class disease-modifying therapy in development for the treatment of different types of interstitial lung diseases…